How The Largest Operator Of Dialysis Centers Kept Granuflo On The Market Even After Knowing Its Deadly Risks

In the realm of healthcare, where trust and patient well-being should reign supreme, a shocking tale of corporate greed and deception has come to light. Fresenius Medical Care, the largest operator of dialysis centers worldwide, has been implicated in a sinister scheme to keep Granuflo, a contaminated dialysis solution, on the market despite knowing its deadly consequences.

GranuFlo: How the Largest Operator of Dialysis Centers Kept GranuFlo on the Market … Even After Reports of Consumer Harm Emerged

5 out of 5

Language	:	English
File size	:	861 KB
Text-to-Speech	:	Enabled
Screen Reader	:	Supported
Enhanced typesetting	:	Enabled
Word Wise	:	Enabled
Print length	:	27 pages
Lending	:	Enabled

FREE

The Genesis of a Toxic Threat

Granuflo, manufactured by Fresenius, was widely used in dialysis treatments to remove waste products from the blood. However, a fatal flaw lurked within this supposedly life-saving solution—it was contaminated with acetate, a toxic substance that could lead to cardiac arrhythmias and death.

Unveiling the Dark Truth

Disturbingly, internal documents obtained through whistleblowers and lawsuits have revealed that Fresenius was aware of the deadly risks associated with Granuflo as early as 2008. Yet, instead of promptly alerting the medical community and halting its distribution, the company chose a path of concealment and deception.

A Litany of Negligence

Fresenius's actions constitute a litany of negligence and corporate malfeasance:

• Failure to Warn: Despite knowing the risks, Fresenius failed to adequately warn doctors and patients about the dangers of Granuflo.
• False Marketing: The company continued to market Granuflo as safe and effective, downplaying the potential for fatal complications.
• Suppression of Evidence: Fresenius allegedly manipulated data and intimidated whistleblowers to suppress the truth about Granuflo.

A Devastating Toll

The consequences of Fresenius's actions have been nothing short of devastating. Thousands of patients have suffered serious health complications, including hundreds who have died as a result of Granuflo contamination.

Justice Prevails

In the face of overwhelming evidence of wrongng, Fresenius has faced numerous lawsuits and government investigations. In 2018, the company agreed to pay $486 million to settle a class-action lawsuit brought by patients and their families.

Lessons Learned

The Granuflo scandal serves as a stark reminder of the importance of corporate accountability and patient safety in the healthcare industry. It highlights the need for:

• Transparency: Healthcare companies must be transparent about the risks associated with their products.
• Accountability: CEOs and executives must be held responsible for corporate malfeasance.
• Patient Advocacy: Patients deserve strong advocates to protect their rights and ensure their well-being.

The story of Fresenius and Granuflo is a sobering indictment of corporate greed and negligence. It is a testament to the power of whistleblowers and the resilience of patients who have fought for justice and accountability. As we move forward, let us remember the lessons learned from this tragedy and demand that the healthcare industry prioritize patient safety above all else.

GranuFlo: How the Largest Operator of Dialysis Centers Kept GranuFlo on the Market … Even After Reports of Consumer Harm Emerged

5 out of 5

Language	:	English
File size	:	861 KB
Text-to-Speech	:	Enabled
Screen Reader	:	Supported
Enhanced typesetting	:	Enabled
Word Wise	:	Enabled
Print length	:	27 pages
Lending	:	Enabled

FREE